This is one of the reasons diets rich in whole plant foods, resistant starches and complex fibres are consistently associated with better metabolic health and improved blood-sugar regulation
Obesity rates in adolescents ages 12-19 have gone up significantly over the past five years, with researchers predicting even greater increases in the near future
The most common side effects for both medications are gastrointestinal: nausea, vomiting, diarrhea, constipation, reflux, and abdominal discomfort
Patients who lose weight may become more active or undertake new exercise regimens, potentially leading to overuse injuries or delayed-onset muscle soreness that may be perceived as joint pain

Semaglutide may be the right starting point if you: Are new to GLP-1 therapy and want to start with the most established option Have a moderate amount of weight to lose Don't have significant insulin resistance or type 2 diabetes Want a well-documented safety profile with years of real-world data Tirzepatide may be the stronger option if you: Have a higher BMI or significant amount of weight to lose Have insulin resistance, prediabetes, or type 2 diabetes Have tried Semaglutide previously with limited results Want the most aggressive metabolic intervention currently available Are dealing with significant visceral fat or metabolic syndrome The Most Important Factor: Medical Guidance The right medication is the one your provider determines is appropriate for your health history, labs, BMI, and goals not the one that sounds more advanced or that someone else is using

The most common side effects observed in trials include nausea, diarrhoea, vomiting, and constipation, similar to other GLP-1 medications, with symptoms typically being mild to moderate and improving over time